Etoricoxib in Ear Nose Throat Surgery
Analgesic Efficacy and Safety of Etoricoxib in Ear Nose Throat Surgery
Sponsor: Merck Sharp & Dohme LLC
This PHASE3 trial investigates Tonsillectomy and is currently ongoing. Merck Sharp & Dohme LLC leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jun 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jan 2021 — Jun 2022 [monthly]
Unknown Status PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jan 2021 [monthly]
Unknown Status PHASE3
First recorded
Oct 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- University of Regensburg
For direct contact, visit the study record on ClinicalTrials.gov .